According to Amicus Therapeutics 's latest financial reports the company's current earnings (TTM) are -$0.16 B. In 2022 the company made an earning of -$0.25 B a decrease over its 2021 earnings that were of -$0.25 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.16 B | -37.98% |
2022 | -$0.25 B | 0.2% |
2021 | -$0.25 B | -11.92% |
2020 | -$0.28 B | -22.94% |
2019 | -$0.36 B | 1.95% |
2018 | -$0.35 B | -22.27% |
2017 | -$0.45 B | 120.39% |
2016 | -$0.21 B | 54.24% |
2015 | -$0.14 B | 88.63% |
2014 | -$70.04 M | 10.92% |
2013 | -$63.15 M | 21.36% |
2012 | -$52.03 M | 8.3% |
2011 | -$48.05 M | -14.33% |
2010 | -$56.08 M | 753.76% |
2009 | -$6.57 M | -83.31% |
2008 | -$39.36 M | -4.4% |
2007 | -$41.17 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Novo Nordisk NVO | $15.42 B | -10,379.35% | ๐ฉ๐ฐ Denmark |
Biogen BIIB | $1.29 B | -963.95% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $7.53 B | -5,119.97% | ๐ฌ๐ง UK |
Lexicon Pharmaceuticals
LXRX | -$0.16 B | 5.17% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | -$0.16 B | 0.11% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $0.18 B | -225.62% | ๐บ๐ธ USA |